If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact email@example.com.
Choose a social network to share with, or copy the shortened URL to share elsewhere
Secukinumab is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation that is not controlled well enough with NSAIDs, in adults for whom TNF-alpha inhibitors are not suitable or do not control the condition well enough.
Customise your preferences for any tracking technology
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.